Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Sirona Biochem Corp

Healthcare US SRBCF

0.0051USD
0.00(0%)

Last update at 2026-06-02T20:00:00Z

Day Range

0.010.01
LowHigh

52 Week Range

0.00130.07
LowHigh

Fundamentals

  • Previous Close 0.0051
  • Market Cap11.13M
  • Volume50000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.25556M
  • Revenue TTM-0.01636M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.08149M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Income before tax -3.55185M -2.31202M -4.14080M -4.55578M -1.15314M
Minority interest - - - - 0.00000M
Net income -3.55780M -2.30633M -4.13372M -4.54957M -1.27325M
Selling general administrative 2.67M 1.08M 2.60M 2.86M 1.02M
Selling and marketing expenses - - - - -
Gross profit 0.67M 0.27M 0.11M 0.14M 1.28M
Reconciled depreciation 0.00909M 0.00946M 0.00970M - 0.00000M
Ebit -3.53127M -2.28858M -4.12927M -4.19879M -0.85627M
Ebitda -3.52218M -2.27913M -4.11958M -4.44355M -0.91198M
Depreciation and amortization 0.00909M 0.00946M 0.00970M - -
Non operating income net other - - - - 0.00000M
Operating income -3.53127M -2.28858M -4.12927M -4.44355M -0.91198M
Other operating expenses 4.21M 2.56M 4.28M 4.60M 2.22M
Interest expense 0.03M 0.00333M 0.01M 0.12M 0.23M
Tax provision 0.00595M -0.00568M -0.00708M -0.00621M 0.12M
Interest income - - 0.04M - -
Net interest income -0.02700M -0.00333M 0.03M -0.11674M -0.22677M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 0.00595M -0.00568M -0.00708M -0.00621M 0.12M
Total revenue 0.67M 0.27M 0.11M 0.14M 1.28M
Total operating expenses 4.21M 2.56M 4.28M 4.60M 2.22M
Cost of revenue - - - - 0.06M
Total other income expense net 0.01M -0.01187M 0.00160M 0.03M 0.02M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -3.55780M -2.30633M -4.13372M -4.54957M -1.27325M
Net income applicable to common shares -3.55780M -2.30633M -4.13372M -4.54957M -1.27325M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2023-10-31 2022-10-31 2021-10-31 2020-10-31 2019-10-31
Type yearly yearly yearly yearly yearly
Date 2023-10-31 2022-10-31 2021-10-31 2020-10-31 2019-10-31
Total assets 1.03M 1.29M 1.29M 2.14M 4.26M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.00639M - - - -
Total liab 3.54M 1.08M 1.38M 2.09M 2.07M
Total stockholder equity -2.51137M 0.21M -0.09702M 0.05M 2.19M
Deferred long term liab - - - - -
Other current liab 0.11M 0.18M 0.11M 0.11M 0.10M
Common stock 34.66M 34.49M 31.21M 29.08M 28.52M
Capital stock 34.66M 34.49M 31.21M 29.08M 28.52M
Retained earnings -43.90076M -41.35757M -37.79976M -35.49343M -31.35971M
Other liab - 0.12M 0.13M 0.12M 0.10M
Good will - - - - -
Other assets 0.00000M - - - -
Cash 0.57M 0.42M 0.78M 1.54M 3.73M
Cash and equivalents - - - - -
Total current liabilities 1.87M 0.86M 0.74M 1.03M 0.92M
Current deferred revenue - - - - -
Net debt 1.61M 0.05M 0.07M -0.29399M -2.18594M
Short term debt 0.64M 0.37M 0.34M 0.30M 0.50M
Short long term debt 0.64M 0.34M 0.30M 0.26M 0.47M
Short long term debt total 2.18M 0.47M 0.85M 1.24M 1.55M
Other stockholder equity 7.40M 7.31M 6.55M 6.56M 5.06M
Property plant equipment - 0.02M 0.03M 0.04M -
Total current assets 1.02M 1.27M 1.26M 2.10M 4.26M
Long term investments - - - - -
Net tangible assets - 0.21M -0.09702M 0.05M 2.19M
Short term investments 0.00073M - - - 0.00073M
Net receivables 0.00661M 0.80M 0.44M 0.50M 0.46M
Long term debt 1.54M 0.09M 0.47M 0.85M 0.94M
Inventory -0.43856M - - - -
Accounts payable 1.12M 0.32M 0.30M 0.62M 0.31M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.67580M -0.22413M -0.05771M -0.10154M -0.03369M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00000M - - - 0.00000M
Deferred long term asset charges - - - - -
Non current assets total 0.00902M 0.02M 0.03M 0.04M 0.00000M
Capital lease obligations 0.00589M 0.04M 0.08M 0.13M 0.14M
Long term debt total - - - - -
Breakdown 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Type yearly yearly yearly yearly yearly
Date 2022-10-31 2021-10-31 2020-10-31 2019-10-31 2018-10-31
Investments - - -0.04697M - 0.00000M
Change to liabilities 0.09M -0.29469M 0.41M 0.06M -0.02169M
Total cashflows from investing activities - - -0.04697M -0.04697M -0.04697M
Net borrowings -0.33837M -0.30826M -0.13338M -0.24060M -0.21972M
Total cash from financing activities 2.04M 1.45M -0.04596M 6.96M 0.72M
Change to operating activities -0.02262M 0.05M 0.02M 0.09M -0.02269M
Net income -3.55780M -2.30633M -4.13372M -4.54957M -1.27325M
Change in cash -0.35649M -0.75787M -2.19877M 3.40M 0.07M
Begin period cash flow 0.78M 1.54M 3.73M 0.34M 0.27M
End period cash flow 0.42M 0.78M 1.54M 3.73M 0.34M
Total cash from operating activities -2.17751M -2.15823M -2.11210M -3.55949M -0.65380M
Issuance of capital stock - - 0.00000M 3.14M 0.60M
Depreciation 0.00909M 0.00946M 0.00970M -0.08622M -0.11445M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables -0.36043M 0.05M -0.03450M -0.14538M 0.41M
Sale purchase of stock - - - - 0.00000M
Other cashflows from financing activities 2.38M 1.76M 0.09M 4.07M 0.12M
Change to netincome 1.67M 0.34M 1.62M 0.99M 0.32M
Capital expenditures 0.00000M 0.00000M 0.05M 0.05M 0.05M
Change receivables - - - - 0.00000M
Cash flows other operating - - - - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - - - 0.00000M
Change in working capital -0.29548M -0.19844M 0.39M 0.00046M 0.36M
Stock based compensation 1.46M 0.33M 1.62M 1.06M 0.12M
Other non cash items 0.20M - 0.00246M -0.06112M 0.13M
Free cash flow -2.17751M -2.15823M -2.15907M -3.55949M -0.65380M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
SRBCF
Sirona Biochem Corp		 - -% 0.0051 - - 360.26 36.93 447.50 -5.7275
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Sirona Biochem Corp., a cosmetic ingredient and drug discovery company, develops and sells cosmetic and pharmaceutical active ingredients in Canada and France. Its programs include cosmetic skin lightener and diabetes drug; and other projects comprise the development of an anti-aging/cell protection library, novel anti-wrinkle compound, and anti-viral program. The company was formerly known as High Rider Capital Inc. and changed its name to Sirona Biochem Corp. in May 2009. Sirona Biochem Corp. was incorporated in 2006 and is headquartered in Vancouver, Canada.

Sirona Biochem Corp

595 Burrard Street, Vancouver, BC, Canada, V7X 1L4

Key Executives

Name Title Year Born
Dr. Howard J. Verrico M.D., Ph.D. Founder, Chairman, CEO & Sec. 1961
Mr. Christopher D. Hopton C.G.A., C.P.A. CFO & Director 1966
Dr. Géraldine Deliencourt-Godefroy Ph.D. Chief Scientific Officer & Director NA
Ms. Michelle Seltenrich MBA VP of Operations NA
Dr. Brett A. Premack Ph.D. Scientific Consultant NA
Dr. Howard J. Verrico M.D., Ph.D. Founder, Chairman of the Board, CEO & Secretary 1961
Mr. Christopher D. Hopton C.G.A., CPA CFO & Director 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions